Vaccine Emerging Markets

Meet us at the 2nd Annu­al Pha­cil­i­tate Part­ner­ing for Vac­cine Emerg­ing Mar­kets event in Ams­ter­dam, May 28th ‑29th or con­tact us pre­vi­ous­ly for a per­son­al meet­ing!

We look for­ward to meet­ing you!

EU Research Project “Nano3Bio” has Started – “Huge Potential” through Biotechnology

ARTES Biotech­nol­o­gy GmbH is part of the inter­na­tion­al con­sor­tium

While the oil is slow­ly but sure­ly run­ning out, renew­able resources are becom­ing increas­ing­ly impor­tant. In future, the bio­log­i­cal pro­duc­tion of raw mate­ri­als has to play an even greater role to meet the needs in an envi­ron­men­tal­ly friend­ly man­ner. An inter­na­tion­al con­sor­tium of researchers and com­pa­nies now ris­es to this chal­lenge. Its goal is the biotech­no­log­i­cal pro­duc­tion of so-called chi­tosans, which are used as raw mate­ri­als for med­i­cine, agri­cul­ture, water treat­ment, cos­met­ics, paper and tex­tile indus­tries as well as many oth­er fields of appli­ca­tion. To tap this poten­tial, the Euro­pean Com­mis­sion sup­ports the research project “Nano3Bio” with a total of almost 9 mil­lion Euros up to 2017. In addi­tion to the experts from ARTES, uni­ver­si­ties and research insti­tutes as well as com­pa­nies from Bel­gium, Den­mark, France, Ger­many, India, The Nether­lands, Spain and Swe­den are involved. They recent­ly met to kick off the project in Mün­ster, Ger­many.

The Nano3Bio project is mak­ing a sci­en­tif­ic dream come true, because this strong con­sor­tium will be able to achieve a break­through from basic research to the biotech­no­log­i­cal pro­duc­tion of chi­tosans”, says Pro­fes­sor Dr. Bruno Moer­schbach­er, biol­o­gist at the Uni­ver­si­ty of Mün­ster and coor­di­na­tor of the project.

ARTES Biotechnology joins TA101 GOCLIN

A lead­ing con­sor­tium of indus­tri­al part­ners has been award­ed a grant by the Sev­enth Frame­work Pro­gram of the Euro­pean Union for an inno­v­a­tive research and devel­op­ment project “TA101 GOCLIN: Clin­i­cal devel­op­ment of TA-101 for the treat­ment of rheuma­toid arthri­tis“ (#606352). The aim of this Project is to take TA101, a small domain anti­body devel­oped by TechnoPhage, into the clin­i­cal stage of devel­op­ment for rheuma­toid arthri­tis (RA) and devel­op a nov­el mode of admin­is­tra­tion for the mar­ket of bio­log­ic ther­a­peu­tics. The project is fore­cast­ed for com­ple­tion in 2015, with a total dura­tion of 26 months. The total bud­get is EUR 1,72 mil­lion cor­re­spond­ing to a total Euro­pean fund­ing of EUR 1,36 mil­lion.

TA101 GOCLIN has mobi­lized the crit­i­cal mass of sev­en indus­tri­al part­ners from 5 Euro­pean coun­tries. These part­ners are from Bel­gium, France, Ger­many, The Nether­lands and Por­tu­gal.

Amspar B.V will design and devel­op an inte­grat­ed micronee­dle patch com­bi­na­tion loaded with TA_101. In this regard, Amspar will close­ly work togeth­er with Lab­o­ra­toires Plas­to San­té (expert in phar­ma­ceu­ti­cal patch devel­op­ment) and Micro­Cre­ate BV (micronee­dle array man­u­fac­tur­ing).
Q‑Biologicals NV togeth­er with ARTES Biotech­nol­o­gy GmbH will devel­op a suit­able micro­bial expres­sion host and man­u­fac­tur­ing process. cGMP mate­r­i­al for clin­i­cal tri­als will be pro­duced by Q‑Biologicals.
Clin­i­cal tri­als will be con­duct­ed by SGS Life Sci­ence Ser­vices.

ARTES Biotechnology and Bio Farma announce collaboration in vaccine development

ARTES and Bio Far­ma announced today to join forces for the devel­op­ment and man­u­fac­tur­ing of vac­cine can­di­dates. The agreed col­lab­o­ra­tion involved the strength of both part­ners. ARTES is spe­cial­ized in cell line and process devel­op­ment, VLP based vac­cines as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion process­es where­as Bio Far­ma is involved in the man­u­fac­tur­ing of vac­cines, serum and oth­er bio­log­i­cal prod­ucts for the Indone­sian domes­tic and inter­na­tion­al mar­kets.

Under this com­mit­ment a first agree­ment for VLP based vac­cine tech­nol­o­gy trans­fer was signed on July 1st in Ban­dung, Indone­sia.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. Bio Far­ma is a strong and reli­able phar­ma­ceu­ti­cal part­ner and the only vac­cine and anti­s­era pro­duc­er for humans in Indone­sia. We are more than con­fi­dent, that we along with Bio Far­ma will devel­op vac­cines high­ly rel­e­vant for the Indone­sian and neigh­bor­ing mar­kets. We expect that espe­cial­ly devel­op­ments based on our Metavax® tech­nol­o­gy will con­tribute to Bio Farma´s vac­cine port­fo­lio”, Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotech­nol­o­gy.

Metavax® is a patent pro­tect­ed VLP tech­nol­o­gy, based on mod­i­fi­ca­tions to duck hepati­tis B virus. The approach elic­its a high­ly potent immune response and there­fore a broad­er pro­tec­tion than the cur­rent­ly avail­able VLP approach­es.
ARTES´Metavax®platform is suit­able for the devel­op­ment and pro­duc­tion of safe and cost-effec­tive vac­cines.

Mean­while, Gov­ern­ment of Indone­sia, rep­re­sent­ed by Min­istry of Health, Min­istry of Edu­ca­tion and Cul­ture and Min­istry of Research and Tech­nol­o­gy, ful­ly sup­ports this part­ner­ship and will assist in aspects of pol­i­cy to accel­er­ate the devel­op­ment of vac­cines in Indone­sia. The com­mit­ment is deliv­ered at the Nation­al Vac­cine Research Forum, on 2–3 July 2013 in Jakar­ta.

ARTES Biotechnology and Midas Pharma signed Cooperation Contract

ARTES announced the col­lab­o­ra­tion with Midas for strate­gic mar­ket­ing oppor­tu­ni­ties. Aim of the coop­er­a­tion is the find­ing of suit­able part­ners for defined phar­ma­ceu­ti­cals projects like vac­cine and phar­ma­ceu­ti­cal tar­get devel­op­ment or trans­fer of Biosim­i­lar process­es.

ARTES is spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try where­as Midas is an inde­pen­dent mar­ket­ing and dis­tri­b­u­tion com­pa­ny, which sup­ports clients in find­ing poten­tial part­ners and mar­kets.

We are con­fi­dent, that we could, togeth­er with Midas’ world­wide rep­re­sen­ta­tives, break into new mar­kets. Espe­cial­ly our vac­cine devel­op­ment plat­form Metavax® has strong capa­bil­i­ties. The Metavax® plat­form is suit­able for the devel­op­ment and pro­duc­tion of cost-effec­tive vac­cines and there­fore inter­est­ing for mar­kets where price is an issue”, Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES point­ed out. “The high­ly expand­ed net­work of Midas will open for us new oppor­tu­ni­ties cur­rent­ly in regions where we not yet in. We are very pleased that, with Midas, we have been able to acquire a very com­pe­tent and reli­able part­ner.”

ARTES Biotechnology issued New Patent in Australia for VLP Technology

ARTES Biotech­nol­o­gy spe­cial­ized in micro­bial cell line and process devel­op­ment as well as in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal indus­try is pleased to announce the issuance of a new patent for their VLP plat­form. The patent will fur­ther strength­en the Metavax® plat­form of the com­pa­ny. In com­bi­na­tion with the expres­sion plat­form Hansenu­la Metavax® is a unique tool for the devel­op­ment of afford­able, safe and effec­tive vac­cines.
“Our intel­lec­tu­al prop­er­ty strat­e­gy is to pro­vide mul­ti­ple lay­ers of pro­tec­tion for our tech­nol­o­gy plat­form port­fo­lio. We believe that this new patent will have addi­tion­al rein­force­ment to our exist­ing patent estate and for our ser­vice we offer clients for vac­cine devel­op­ment,” said Dr. Melanie Pio­ntek, Busi­ness Devel­op­ment Direc­tor of ARTES.

New website!

ARTES has launched a new web­site, incor­po­rat­ing new con­tent to give a bet­ter view on the cur­rent busi­ness and added offer.

The new site espe­cial­ly fea­tures an overview of ARTES’ busi­ness expan­sion in tech­nol­o­gy trans­fer and its Metavax® approach for VLP-based vac­cine devel­op­ment.

Strategic cooperation between ARTES Biotechnology and PAC

Artes and PAC join forces and com­bine their tech­nolo­gies and know-how.

ARTES Biotech­nol­o­gy spe­cial­izes in recom­bi­nant pro­tein pro­duc­tion, process devel­op­ment in micro­bial expres­sion sys­tems and is a tech­nol­o­gy provider for phar­ma­ceu­ti­cal process­es, while PAC (Peschek Ana­lyt­ic Con­sult­ing) is high­ly skilled in the field of pro­tein analy­sis and qual­i­ty con­trol. Togeth­er with PAC, ARTES will now prospec­tive­ly offer analy­sis of prod­uct qual­i­ty con­trol along side deter­mi­na­tion and quan­tifi­ca­tion of by-prod­ucts and/or process relat­ed resid­u­als. The method analy­sis port­fo­lio of PAC allows ARTES to offer method devel­op­ment and val­i­da­tion in accor­dance with GMP guide­lines in the fol­low­ing ana­lyt­i­cal meth­ods as HPLC-UV/DAD, Mass Spec­trom­e­try Ion Trap (LC-ESI/APCI MS/MS), Mass spec­trom­e­try Quadru­pole (LC-ESI-MS), Gas Chro­matog­ra­phy-Mass Spec­trom­e­try, Cap­il­lary Elec­trophore­sis, Dynam­ic Light Scat­ter­ing and Elec­tron Microscopy.

Strategic collaboration deal for vaccine development

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion and process devel­op­ment in micro­bial expres­sion sys­tems, start­ed a devel­op­ment col­lab­o­ra­tion for two vac­cines togeth­er with glob­al bio­phar­ma-ceu­ti­cal com­pa­ny Cru­cell. Cru­cell is focused on the research & devel­op­ment, pro­duc­tion and mar­ket­ing of vac­cines and anti­bod­ies against infec­tious dis­ease world­wide.

Aim of the long-term research coop­er­a­tion is a new-prod­uct devel­op­ment on the basis of ARTES’ virus like par­ti­cle (VLP) and the well-estab­lished Hansenu­la poly­mor­pha expres­sion sys­tem fit­ting to Crucell’s vac­cine port­fo­lio. The Hansenu­la sys­tem is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and is rec­om­mend­ed by the WHO for hepati­tis B vac­ci­na­tion cam­paigns. In com­bi­na­tion, the unique yeast based VLP approach builds a new and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines.

Under the terms of the long-term research col­lab­o­ra­tion ARTES is respon­si­ble for deliv­ery of the pro­duc­tion cell lines and process­es to Cru­cell.

ARTES and NL join in a strategic collaboration and co-marketing alliance

ARTES, spe­cial­ized in recom-binant pro­tein pro­duc­tion and process devel­op­ment from yeast expres­sion sys­tems and the US based com­pa­ny NL Biotech-nolo­gies, own­er and spe­cial­ized in cer­tain tech-nolo­gies for pro­duc­tion of vac­cines and diag­nos­tic pro­teins start­ed a strate­gic col­lab­o­ra­tion.

With sign­ing this col­lab­o­ra­tion agree­ment the two com­pa­nies com­bine their know-how and tech­nolo­gies in yeast expres-sion, process and vac­cine devel­op­ment. The direct and notice­able aim is the mar­ket­ing of effi­cient and cost effec­tive vac­cines and diag­nos­tics pro­teins. The first prod­uct that is avail­able right from the start is a Hansenu­la poly­mor­pha derived Hepati­tis E vac­cine. Proof-of-prin­ci­ple and ani­mal stud­ies (mice and macaques) have been done and shown very good result and high immune answers.

The Hepati­tis E trans­mis­sion is a per­son-to-per­son one, nor­mal­ly trig­gered to the fecal-oral route. Infec­tions occur because of con­sump­tion of con­t­a­m­i­nat­ed water and inges­tion of raw or uncooked food – there­fore it is a dis­ease most com­mon in devel­op­ing coun­tries,“ Vitaly Gra­novskiy, man­ag­ing direc­tor of NL car­ried out. And Dr. Michael Pio­ntek, man­ag­ing direc­tor of ARTES added, ”With the Hepati­tis E process we have anoth­er reli­able and cost-effi­cient VLP-based pro­duc­tion process in our port­fo­lio. Like for HepB and avian flu, the man­u­fac­tur­ing costs for this vac­cine are low because of the effec­tive tech­nol­o­gy behind. In our mind, it should be an inter-est­ing process par­tic­u­lar for devel­op­ing coun­tries. “

The part­ners are now look­ing for com­pa­nies to out-license the process.